Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of antithrombin supplementation during ECMO
2016-004534-23Phase 3Completed
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of antithrombin III in respiratory failure, sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: Heparin dose required to maintain target aPTT ratio. Started Mar 2019; status: completed.
02
Drugs
antithrombin III
03
Conditions
respiratory failure
Beyond the preview
Go deeper on 2016-004534-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004534-23.